Other red cell antibodies may rarely cause mild extravascular hemolysis but not intravascular ... physician and the transfusion department/laboratory must be notified immediately and the reactions ...
But it's the only monotherapy -- oral monotherapy to provide extravascular and intravascular hemolysis control ...
reported in the ALPHA trial evaluating VOYDEYA as add-on to ULTOMIRIS or SOLIRIS in patients with PNH experiencing clinically significant extravascular hemolysis (EVH) and separately in the ...
“The extravascular, intrapericardial balloon implant requires no large vessel access, and the system avoids many of the current standard of care complications, such as major bleeding, hemolysis ...
New, long-term data for VOYDEYA™ as add-on to ULTOMIRIS ® or SOLIRIS ® will show low rate of breakthrough hemolysis events and sustained improvements in quality-of-life measures in PNH with ...
VOYDEYA ™ as add-on to ULTOMIRIS ® or SOLIRIS ® for the subset of patients with PNH experiencing clinically significant extravascular hemolysis. Further, new insights from our robust pipeline ...
Microangiopathic hemolytic anemia (MAHA) occurs when turbulence in the blood destroys red blood cells. This leads to symptoms such as tiredness and shortness of breath. Certain treatments are ...
Transitioning from vemircopan to ravulizumab can lead to severe extravascular hemolysis in patients with PNH. The treatment of paroxysmal nocturnal hemoglobinuria (PNH) is advancing with proximal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback